QIAGEN and DiaSorin have secured approval from the US Food and Drug Administration (FDA) for use of QuantiFERON-TB Gold Plus assay on the automated LIAISON XS platform.

The QuantiFERON assay secured the FDA approval for use on DiaSorin’s LIAISON XL analyser in 2019.

The additional approval enables QIAGEN and DiaSorin to provide a suite of automation platforms for TB testing options to customers, ranging from small healthcare clinics to larger hospitals and reference laboratories.

Developed by QIAGEN and DiaSorin, LIAISON QuantiFERON-TB Gold Plus is an interferon-gamma release assay (IGRA) is said to provide streamlined laboratory automation for latent TB screening.

The assay detects for interferon-gamma released from T-cells that have encountered TB bacteria.

QIAGEN CEO Thierry Bernard said: “QuantiFERON-TB Gold Plus continues to set new standards in the global fight against TB, a disease that remains a persistent killer and impacts people around the world.

“Our partnership with DiaSorin has enabled customers to absorb the increasing demand for TB detection with access to a proven automation solution on the LIAISON XL platform, especially in larger reference labs and hospitals.

“The addition of the LIAISON XS platform will open up new joint opportunities for us to reach new customer segments requiring lower-throughput options.”

In April this year, QIAGEN and DiaSorin launched the LIAISON LymeDetect assay for markets accepting the CE Mark.

The assay is designed as an aid to detect early Lyme Borreliosis infection (Lyme) on LIAISON analyser systems.

By combining both humoral and cellular immunity through a specific interferon-gamma release assay, the LIAISON LymeDetect assay enables significantly improved sensitivity and earlier detection of the infection.